This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leiby, J. M. Articles by Grever, M. R. Search for Related Content PubMed PubMed Citation Articles by Leiby, J. M. Articles by Grever, M. R.

Phase II Trial of 9-ß-D-Arabinofuranosyl-2-fluoroadenine 5'-Monophosphate in Non-Hodgkin's Lymphoma: Prospective Comparison of Response with Deoxycytidine Kinase Activity¹

The Ohio State University, Comprehensive Cancer Center, 410 West 12th Avenue, Columbus, Ohio 43210

A phase II study of 9-ß-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate was done in non-Hodgkin's lymphoma with a loading dose/continuous intravenous infusion schedule, consisting of a 20 mg/m² loading dose followed by a continuous i.v. infusion of 30 mg/m²/24 h for 48 h. The loading dose was held constant while the continuous i.v. dose was escalated or decreased as appropriate for toxicity. Twenty-six patients were entered on the study; 25 are evaluable for response. The patients' median age was 61 years (range 25 to 73); their mean performance status was 1.1. They had received a mean of 2.6 prior chemotherapeutic regimens, and six also had prior radiation therapy. There was one complete response lasting 9+ months, and there were seven partial responses lasting 20, 13, 11, 11, 10, 5, and 2 months (response rate 32%). Toxicity was acceptable and consisted mainly of myelosuppression. 9-ß-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate is dephosphorylated in vivo and then is thought to be activated intracellularly to 9-ß-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. The rate-limiting enzyme is deoxycytidine kinase. Deoxycytidine kinase activity was determined on pretreatment tumor samples for correlation with response. There was no difference between the values for responders and nonresponders. There was a trend for higher values in more malignant histological subtypes.

¹ Supported in part by NCI Grants RO1-CA-36331, P30-CA-16058, and CA-09338.

² To whom requests for reprints should be addressed, at Room N1014, Doan Hall, 410 West Tenth Avenue, Columbus, OH 43210.

Received 6/20/86. Revised 1/30/87. Accepted 2/19/87.

This article has been cited by other articles:

				C. Alliot Fludarabine Versus Cyclophosphamide, Vincristine, and Prednisone in Recurrent Low-Grade Lymphomas J. Clin. Oncol., July 1, 2003; 21(13): 2626 - 2626. [Full Text] [PDF]

				E. Mansson, T. Spasokoukotskaja, J. Sallstrom, S. Eriksson, and F. Albertioni Molecular and Biochemical Mechanisms of Fludarabine and Cladribine Resistance in a Human Promyelocytic Cell Line Cancer Res., December 1, 1999; 59(23): 5956 - 5963. [Abstract] [Full Text] [PDF]

				P. Fidias, B. A. Chabner, and M. L. Grossbard Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders Oncologist, June 1, 1996; 1(3): 125 - 139. [Abstract] [Full Text] [PDF]